Phase 1 trial of MGC028, an ADAM9-directed Topo I inhibitor ADC for advanced solid tumors.

This Phase 1 study led by MacroGenics evaluates safety, tolerability, and optimal dosing of MGC028 in adult patients with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors. Participants receive treatment every three weeks with careful monitoring of side effects, blood tests, and imaging. The trial employs dose escalation and expansion cohorts across multiple tumor types, including colorectal, pancreatic, and non-small cell lung cancers, to assess if MGC028 can control disease progression.